Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06163469
Other study ID # 2000034836
Secondary ID 000
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2024
Est. completion date December 31, 2025

Study information

Verified date April 2024
Source Yale University
Contact Joshua Sterling, MD, MSc
Phone 203-737-3619
Email joshua.sterling@yale.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the feasibility and tolerability of 0.05% Chlorhexidine Gluconate (CGH) bladder instillations in an outpatient setting at the time of suprapubic catheter (SPC) exchange in patients with history of recurrent urinary tract infections (UTI). The main questions are: 1. is instillation of 150mL of CGH for five-minute duration at the time of SPC exchange feasible in an outpatient setting and tolerable for patients. 2. does this protocol decrease the rate of unplanned health care visits and improve patient quality of life. Patients will undergo the treatment protocol during their routine suprapubic catheter exchanges.


Description:

Bacterial colonization is present in up to 95% of chronically catheterized patients. Although a positive urine culture collected from an indwelling catheter is not in isolation indicative of an acute urinary tract infection (UTI), long term catheter use is associated with increased rates of recurrent urinary tract infections (rUTI), pyelonephritis, and bacteremia. Using antibiotics for prevention of infections in this patient population can be challenging given the side effects, cost, and emergence of resistant bacteria with antibiotic therapy. To limit systemic side effects, intravesical irrigation is a promising route of medication administration. The use of a non-antibiotic anti-microbial at the time of SPC exchange would eliminate the obstacles of non-compliance and antibiotic resistance associated with antibiotic irrigation for preventive therapy. Irrisept, a 0.05% Chlorhexidine Gluconate (CHG) irrigation in sterile water, could be a promising agent to reduce symptomatic UTIs and unplanned tube changes in chronically catheterized patients. The proposed route of intravesical instillation involves the administration of a therapeutic agent directly into the bladder via a urinary catheter. This route allows for local contact with bladder mucosa and urinary pathogens. It is a currently accepted route of administration used for therapeutics in urologic conditions including, but not limited to UTI prophylaxis, bladder cancer, hemorrhagic cystitis, and interstitial cystitis. Benefits of intravesical instillation include maximizing exposure of the therapeutic within the bladder while limiting systemic absorption and side effects. A volume 150cc is based on current clinical administration of bladder instillations. Current intravesical drug delivery is most commonly utilized in volumes 50-150cc for in-office instillation. Population studies of normal volunteers demonstrate that 1st bladder sensation occurs between 125-200cc with subsequent desire to void occurring between 170-370cc. Increasing instillation volumes greater than 150cc, especially in the chronically catheterized population, can lead to patient discomfort or dysreflexia and inability to tolerate the therapy without analgesia or anesthetic.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date December 31, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Indwelling suprapubic catheter with insertion date at least 1 year prior to study enrollment date. - History of urinary tract infections, treated for at least 1 positive urine culture in last 6 months Exclusion Criteria: - Current radiographic evidence of urolithiasis - History of vesicoureteral reflux - History of renal transplantation - History of bladder augmentation - Inability to stop use of other rUTI prophylaxis treatments for the duration of their trial enrollment - Life expectancy of less than 12 months prior to consent. - Known hypersensitivity or allergy to chlorhexidine. - Women who are pregnant or breastfeeding.

Study Design


Intervention

Device:
Bladder instillation with Irrisept
9 months of bladder instillations (3 months of saline and 6 months of chlorohexidine gluconate)

Locations

Country Name City State
United States Yale New Haven Health New Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University Irrimax Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary tolerability and feasibility of CGH bladder instillation Tolerability and feasibility of CGH bladder instillation of 150mL for five-minute duration at the time of SPC exchange. Volumes of each instillation and tolerated dwell time will be recorded with each instillation. 9 months
Secondary Incidence of bacteriuria Urine cultures will be taken at each SPC exchange for nine months while undergoing irrigations (3 months with saline and 6 months with Irrisept) and for an additional six months following completion of instillation treatment. Incidence of bacteriuria prior to the start of instillation will be compared to the incidence during the instillation phase and observation phase. monthly for 15 months
Secondary effect of chlorhexidine gluconate catheter biofilm flora the catheter tips will be sent for culture at each exchange. results between the saline and CGH irrigations will be compared up to 9 months
Secondary Incidence of symptomatic UTI Participants will complete a validated UTI symptom assessment at the time of instillation and then three days later when the urine culture is finalized. Responses will be compared to each participants self reported typical UTI symptoms to differentiate between asymptomatic bacteruria and symptomatic UTI. up to 15 months
Secondary impact of mechanical bladder washing Urine culture results and patient questionnaires during the saline irrigations will be compared to those during the CGH irrigation up to 9 months
Secondary effect of chlorhexidine changes the microbiome of the bladder Urine culture data from the CGH instillation phase will be compared to culture data from the saline irrigation and observational period. Changes in the dominant bacteria from each culture will be reported. up to 15 months
Secondary unplanned healthcare contact between routine SPC exchanges At each SPC change and instillation an interval history will be taken any unplanned healthcare utilization (I.e. emergency room, primary care, and urology calls and visits) will be recorded. The number of recorded events during the instillation and observation phases will be compared. up to 15 months
Secondary patient quality of life and overall satisfaction participants will complete a validated six question quality of life questionnaire at months 0, 3, 6, 9, 12, and 15. Changes in the sum total (lower the sum the higher the quality of life) and individual responses will be tabulated. up to 15 months
See also
  Status Clinical Trial Phase
Withdrawn NCT05538273 - Optimal Management of Urinary Catheter in Gyn Onc
Recruiting NCT05065255 - Study of the Criteria for Choosing Speedicath Catheters During the Initiation of Self-catheterization
Completed NCT04236596 - Pudendal Nerve Mapping Towards Improved Neuromodulation for Urinary Retention N/A
Completed NCT05526651 - Improvement of Urinary Retention Symptoms With Electroacupuncture Therapy N/A
Not yet recruiting NCT06070545 - The Effect of Modified Supine Position on Urinary Elimination After Percutaneous Coronary Intervention N/A
Recruiting NCT03314025 - Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery Phase 2
Recruiting NCT05439902 - Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women N/A
Enrolling by invitation NCT05259800 - Peppermint Oil for Urinary Retention N/A
Recruiting NCT06417346 - Comparison of Laparoscopic and Open Inguinal Hernia Repair in Elderly Patients N/A
Completed NCT03296280 - Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
Completed NCT04715971 - Urinary Retention on an Acute Geriatric Hospitalisation Unit.
Completed NCT03302936 - Assessing Pyridium for Post-Sling Urinary Retention Phase 4
Completed NCT02886143 - Effect of Active vs. Passive Voiding Trials on Time to Discharge, Urinary Tract Infection, and Urinary Retention Phase 3
Completed NCT02749188 - Evaluation of Bladder Stimulation as a Noninvasive Technique of Urine Collection in Infant Who Have Not Acquired Walking N/A
Completed NCT01220362 - Effects of Thoracic Epidural Analgesia and Surgery on Lower Urinary Tract Function: A Randomized, Controlled Study N/A
Completed NCT01284361 - Comparison of Two Intermittent Urinary Catheters N/A
Terminated NCT00804557 - Efficacy And Safety Of The Uro-Ease® Urinary Catheter During Clean Intermittent Catheterization N/A
Terminated NCT00563654 - Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up N/A
Terminated NCT00563485 - Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up N/A
Terminated NCT04682366 - The Effect of Tamsulosin on Postoperative Urinary Retention Phase 4